Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia
Study sponsor: Kura Oncology, Inc. · KURA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-11-30Actual
Enrollment · participants44Actual
Source updated2024-07-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.